Doxorubicin Hydrochloride Liposome Injection
Oncology (various cancers)
ApprovedActive
Key Facts
About ForDoz Pharma
ForDoz Pharma is a private CDMO focused on addressing a critical gap in US-based manufacturing capacity for conventional and complex sterile injectables. Founded in 2014 and operational from a facility purchased in 2016, the company has built integrated capabilities to support the full product lifecycle, from development through commercial production. A key milestone was the 2024 FDA approval of its own generic Doxorubicin Hydrochloride Liposome Injection, demonstrating its technical prowess. The company's strategy leverages this proprietary manufacturing experience to attract CDMO clients seeking expertise in complex sterile drug products.
View full company profileTherapeutic Areas
Other Oncology (various cancers) Drugs
| Drug | Company | Phase |
|---|---|---|
| NP-101 | Novatek Pharmaceuticals | Phase 1/2 |
| Biosimilar Bevacizumab | Strides Pharma | Development |
| AVT33 | Alvotech | Early Phase |
| AL008 | Alector | Preclinical |